Novo Nordisk weight-loss drug Wegovy reduced the risk of major cardiovascular events by 20% in a large clinical trial. The company said the results support expanding the drug’s label, but the looming question is whether the data will persuade payers to cover the pricey chronic therapy.
Employers should be looking at obesity as a chronic condition and focus on weight management solutions over weight loss solutions, said Parin Chikani, medical account director for managed markets at Novo Nordisk. He made these comments Tuesday at the Midwest Business Group on Health conference in Chicago.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Novo Nordisk can afford the price cuts prices to several branded and non-branded insulins. Flattening revenue for the pharmaceutical giant’s insulin products is offset by demand for diabetes and obesity drugs from its semaglutide franchise, which continues to grow by leaps and bounds.
High prices have drawn other critics, as well, including President Joe Biden. He renewed his call for a broad price cap during his annual State of the Union address. Pharma companies insist they have been part of the solution.
The FDA approved a change in Rybelsus’s label, allowing the drug to be used as an initial therapy for type 2 diabetes patients. The once-daily pill has already become a blockbuster product for Novo Nordisk.
Novo Nordisk is acquiring global rights to a Ventus Therapeutics drug candidate with potential applications in cardiometabolic disorders such as NASH and chronic kidney disease. The small molecule blocks a protein that has become an attractive target for big pharmaceutical companies, such as Roche and Novartis.
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
Novo Nordisk announced that it will buy Forma Therapeutics, a clinical-stage biotech focused on rare hematologic diseases, in an deal valued at $1.1 billion. The deal is the second billion-dollar sickle cell disease deal the pharmaceutical industry has seen in the last 30 days — Pfizer forked over $5.4 billion in August to buy Global Blood Therapeutics.
Obese patients are more at risk for diabetes, cardiovascular disease, certain cancers and mortality than patients who maintain a healthy weight, and obese patient who develop these chronic conditions usually have more complications. That is why providers and payers must integrate more weight loss strategies in chronic condition care, panelists argued at a Tuesday panel hosted by the Chamber of Commerce.
The acquisition agreement comes exactly two years after the two companies began a wide-ranging alliance focused on developing RNA interference drug for metabolic disorders. The most advanced therapy from that alliance is on track to reach the clinic in 2022.
Novo Nordisk is paying $100 million up front to acquire an experimental Prothena drug being developed to treat heart problems stemming from a misfolded protein. The deal is part of a broader strategy to expand into drugs for cardiovascular disease.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
Walmart struck a deal with Novo Nordisk to offer a heavily discounted, private-label version of its fast-acting analog insulin. But it still doesn’t solve the pricing problems patients have faced, with insulin costs skyrocketing in recent years.
Covid-19 showed how technology can upend the old ways of clinical trials. Panelists at MedCity's INVEST conference said it's highlighting the importance of improving clinical trial diversity so that tests of new therapies and vaccines reflect the population of patients that they will treat in the real world.
Clinical tests of drugs from Gilead Sciences and Novo Nordisk have yielded encouraging results in nonalcoholic steatohepatitis (NASH), and the partners now want to see if the drug combinations help patients in a larger mid-stage study. The planned Phase 2b study expands on a 2019 R&D alliance.
Prominent drug companies have said they want to curb waste and abuse in the 340B Drug Pricing Program. But the top lawyer at HHS is echoing the criticism hospitals have been leveling against the drug companies over access to the program.
The lawsuit follows action by at least a half-dozen drug companies to rein in what they see as waste and abuse in the program, overseen by the Department of Health and Human Services. Meanwhile, the Hospital plaintiffs have a potentially powerful ally in the person picked to head the department under the incoming Biden administration.